InvestorsHub Logo
Followers 17
Posts 2115
Boards Moderated 0
Alias Born 06/18/2007

Re: BuyMyAsk post# 6159

Thursday, 12/18/2014 4:08:45 PM

Thursday, December 18, 2014 4:08:45 PM

Post# of 27424
Go over and take a look at the companies I posted , check out the revenue,
the status of FDA trials etc. ACAD has no revenue to speak of. $25,000.00/Q
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News